About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AlloVir

News headline image
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir Reports First Quarter 2023 Financial Results
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir Appoints Shawn Tomasello to Its Board of Directors
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir Announces Departure of Chief Medical Officer Augustin Melian
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir to Host Virtual Investor Event
From AlloVir
Via Business Wire
News headline image
AlloVir Reports Third Quarter 2021 Financial Results
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir Reports Second Quarter 2021 Financial Results
From AlloVir
Via Business Wire
Tickers ALVR
News headline image
AlloVir Reports First Quarter 2021 Financial Results
From AlloVir
Via Business Wire
Tickers ALVR
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.